Principal Financial Group
JNCE

Principal Financial Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Principal Financial Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,811
Closed -$30K – 2577
2022
Q3 		$30K Sell
12,811
-12,203
-49% -$43.2K ﹤0.01% 2441
2022
Q2 		$76K Buy
25,014
+6,641
+36% +$32.3K ﹤0.01% 2428
2022
Q1 		$125K Sell
18,373
-9,444
-34% -$67.3K ﹤0.01% 2408
2021
Q4 		$232K Sell
27,817
-18,203
-40% -$150K ﹤0.01% 2318
2021
Q3 		$342K Sell
46,020
-1,736
-4% -$10.8K ﹤0.01% 2272
2021
Q2 		$325K Buy
47,756
+10,689
+29% +$88.8K ﹤0.01% 2334
2021
Q1 		$381K Buy
37,067
+2,795
+8% +$30.6K ﹤0.01% 2216
2020
Q4 		$240K Buy
34,272
+2,337
+7% +$18.2K ﹤0.01% 2277
2020
Q3 		$261K Buy
31,935
+15,123
+90% +$93.8K ﹤0.01% 2152
2020
Q2 		$116K Buy
+16,812
New +$90.7K ﹤0.01% 2238

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Principal Financial Group's JNCE Position: Q4 2022 in Review

Principal Financial Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 12,811 shares — an estimated $30K sold.

Principal Financial Group first reported a position in JNCE in Q2 2020 and held it in 10 quarters. The position peaked at $381K in Q1 2021. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • Principal Financial Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Principal Financial Group sold 12,811 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $30K.
  • Principal Financial Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • Principal Financial Group's Jounce Therapeutics, Inc. Common Stock position peaked at $381K in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Principal Financial Group's 13F filing for Q4 2022, filed 9 Feb 2023.